Immunotherapy of acquired hemophilia A

2.

Tiede

A

,

Collins

P

,

Knoebl

P

, et al.

International recommendations on the diagnosis and treatment of acquired hemophilia A

.

Haematologica

.

2020

;

105

(

7

):

1791

-

1801

.

doi:10.3324/haematol.2019.230771

.

3.

Collins

PW

.

Management of acquired haemophilia A

.

J Thromb Haemost

.

2011

;

9

(

suppl 1

):

226

-

235

.

doi:10.1111/j.1538-7836.2011.04309.x

.

4.

Kahle

J

,

Orlowski

A

,

Stichel

D

, et al.

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A

.

Blood

.

2017

;

130

(

6

):

808

-

816

.

doi:10.1182/blood-2016-11-751347

.

5.

Tiede

A

,

Hofbauer

CJ

,

Werwitzke

S

, et al.

Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

.

Blood

.

2016

;

127

(

19

):

2289

-

2297

.

doi:10.1182/blood-2015-09-672774

.

6.

Oleshko

O

,

Werwitzke

S

,

Klingberg

A

, et al.

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

.

Blood Adv

.

2023

;

7

(

1

):

122

-

130

.

doi:10.1182/bloodadvances.2022008071

.

7.

Green

D

,

Lechner

K.

A survey of 215 non-hemophilic patients with inhibitors to factor VIII

.

Thromb Haemost

.

1981

;

45

(

3

):

200

-

203

.

doi:10.1055/s-0038-1650169

.

8.

Green

D.

Cytotoxic suppression of acquired factor VIII:C inhibitors

.

Am J Med

.

1991

;

91

(

5A

):

14S

-

19S

.

doi:10.1016/s0002-9343(91)80142-9

.

9.

Delgado

J

,

Jimenez-Yuste

V

,

Hernandez-Navarro

F

,

Villar

A.

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors

.

Br J Haematol

.

2003

;

121

(

1

):

21

-

35

.

doi:10.1046/j.1365-2141.2003.04162.x

.

10.

Collins

PW

,

Hirsch

S

,

Baglin

TP

, et al;

UK Haemophilia Centre Doctors' Organisation

.

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation

.

Blood

.

2007

;

109

(

5

):

1870

-

1877

.

doi:10.1182/blood-2006-06-029850

.

11.

Borg

JY

,

Guillet

B

,

Le Cam-Duchez

V

,

Goudemand

J

,

Lévesque

H

;

SACHA Study Group

.

Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry

.

Haemophilia

.

2013

;

19

(

4

):

564

-

570

.

doi:10.1111/hae.12138

.

12.

Tiede

A

,

Klamroth

R

,

Scharf

RE

, et al.

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

.

Blood

.

2015

;

125

(

7

):

1091

-

1097

.

doi:10.1182/blood-2014-07-587089

.

13.

Schep

SJ

,

van Dijk

WEM

,

Beckers

EAM

, et al;

Dutch Society of Haemophilia Treaters, The Netherlands

.

Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study

.

Am J Hematol

.

2021

;

96

(

1

):

51

-

59

.

doi:10.1002/ajh.26009

.

14.

Mingot-Castellano

M-E

,

Pardos-Gea

J

,

Haya

S

, et al;

Acquired Haemophilia Spanish Registry of the Spanish Society of ThrombosisHaemostasis (SETH)

.

Management of acquired hemophilia A: results from the Spanish registry

.

Blood Adv

.

2021

;

5

(

19

):

3821

-

3829

.

doi:10.1182/bloodadvances.2021004626

.

15.

Lottenberg

R

,

Kentro

TB

,

Kitchens

CS

.

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

.

Arch Intern Med

.

1987

;

147

(

6

):

1077

-

1081

.

doi:10.1001/archinte.147.6.1077

.

16.

Levesque

H.

Outcome of acquired haemophilia with steroid combined with cyclophosphamide versus steroid combined with rituximab (CREHA study)

. https://clinicaltrials.gov/ct2/show/NCT01808911. Accessed

October

7

,

2023

.

17.

Obaji

S

,

Rayment

R

,

Collins

PW

.

Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A

.

Haemophilia

.

2019

;

25

(

1

):

e59

-

e65

.

doi:10.1111/hae.13658

.

18.

Holstein

K

,

Liu

X

,

Smith

A

, et al.

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

.

Blood

.

2020

;

136

(

3

):

279

-

287

.

doi:10.1182/blood.2019003639

.

19.

Dobbelstein

C

,

Moschovakis

GL

,

Tiede

A.

Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study

.

Ann Hematol

.

2020

;

99

(

9

):

2105

-

2112

.

doi:10.1007/s00277-020-04150-y

.

20.

Simon

B

,

Ceglédi

A

,

Dolgos

J

, et al.

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen

.

Blood

.

2022

;

140

(

18

):

1983

-

1992

.

doi:10.1182/blood.2022016873

.

21.

Reeves

BN

,

Key

NS

.

Acquired hemophilia in malignancy

.

Thromb Res

.

2012

;

129

(

suppl 1

):

S66

-

S68

.

doi:10.1016/S0049-3848(12)70019-1

.

22.

Napolitano

M

,

Siragusa

S

,

Mancuso

S

,

Kessler

CM

.

Acquired haemophilia in cancer: a systematic and critical literature review

.

Haemophilia

.

2018

;

24

(

1

):

43

-

56

.

doi:10.1111/hae.13355

.

23.

Knoebl

P

,

Thaler

J

,

Jilma

P

,

Quehenberger

P

,

Gleixner

K

,

Sperr

WR

.

Emicizumab for the treatment of acquired hemophilia A

.

Blood

.

2021

;

137

(

3

):

410

-

419

.

doi:10.1182/blood.2020006315

.

24.

Shima

M

,

Amano

K

,

Ogawa

Y

, et al.

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

.

J Thromb Haemost

.

2023

;

21

(

3

):

534

-

545

.

doi:10.1016/j.jtha.2022.10.004

.

25.

Tiede

A

,

Kemkes-Matthes

B

,

Knöbl

P.

Should emicizumab be used in patients with acquired hemophilia A?

J Thromb Haemost

.

2021

;

19

(

3

):

637

-

644

.

doi:10.1111/jth.15208

.

26.

Collins

P

,

Baudo

F

,

Knoebl

P

, et al;

EACH2 registry collaborators

.

Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

.

Blood

.

2012

;

120

(

1

):

47

-

55

.

doi:10.1182/blood-2012-02-409185

.

27.

Sun

B

,

Xue

F

,

Feng

Y

, et al.

Outcome of CARE: a 6-year national registry of acquired haemophilia A in China

.

Br J Haematol

.

2019

;

187

(

5

):

653

-

665

.

doi:10.1111/bjh.16128

.